TScan Therapeutics announces preliminary results from ALLOHA Phase 1 trial

TScan Therapeutics (TCRX) announced that preliminary results from the ALLOHA Phase 1 trial of TSC-100 and TSC-101, in patients with acute myeloid leukemia, AML, acute lymphoblastic leukemia, ALL, and myelodysplastic syndrome, MDS, undergoing allogeneic hematopoietic cell transplantation, HCT, with reduced intensity conditioning, will be featured in an oral presentation at the 66th American Society of Hematology, ASH, Annual Meeting and Exposition being held December 7 – 10 in San Diego, CA. All five TSC-treated patients that reached one-year follow-up remained relapse-free and MRD negative as of the data cutoff, consistent with effective elimination of residual cancer cells post-HCT. No dose limiting toxicities occurred following TSC-100 or TSC-101 infusions and safety was similar in the treatment and control arms, with expected post-HCT adverse events.